Tessa Holyoake

Mhairi Copland(Blood Cancer UK), Mark W. Drummond(Beatson West of Scotland Cancer Centre), JEFF EVANS(Intermountain Healthcare), Owen Samson(Cancer Research UK Scotland Institute)

BMJ

September 12, 2017

10.1136/bmj.j4224

Cited by 0

Related Papers

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

|Blood|2006|632

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

|Clinical Cancer Research|2015|355

A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway

|Nature Cell Biology|2013|296

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease.

|Gut|1997|249

Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells

|Lab on a Chip|2009|136